RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions
A second cellular-technology launch in close succession broadens Cellgenic's portfolio into Latin America, the Middle East, Europe, and Southeast Asia, demonstrating a repeatable product-development motion.
MIAMI, FL / ACCESS Newswire / August 27, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the introduction, through its Cellgenic division, of a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets - including Latin America, the Middle East, Europe, and Southeast Asia - subject to applicable local regulatory requirements.
MUSE cells are a class of pluripotent-like stem cells identified in adult tissue and studied for their stress-tolerance and multilineage-differentiation properties. The introduction is intended to give physicians in Cellgenic's target markets access to an additional category of advanced cellular technology alongside the division's existing product offering. The Company is not making therapeutic claims in this announcement.
The MUSE launch follows Cellgenic's August 24, 2026, introduction of a Natural Killer (NK) cell product line and continues a pattern of sequential, technology-specific launches rather than a single one-off announcement.
Operational and Strategic Update
David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc., commented: "MUSE cell science has attracted significant attention across the regenerative medicine research community. Bringing a MUSE cell product line to our international markets is consistent with how we have grown Cellgenic - one differentiated technology at a time, matched to real physician and patient demand."
Two cellular-technology launches in close succession allow RMTG to demonstrate a repeatable product-development and market-entry motion. Management views that capability as a more durable driver of long-term growth than any single product, and a core element of the operating leverage the Company is building across its supply business.
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTCID:RMTG) is a regenerative medicine company operating through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technology across an international network. The Company operates across more than 30 countries. Additional information about the Company's business, operations, and risks is available in its filings with the Securities and Exchange Commission.
About Cellgenic
Cellgenic is the biologics and product-commercialization division of Global Stem Cells Group, developing and distributing advanced cellular Technology, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.
Contact
Investor Relations Regenerative Medical Technology Group, Inc. [email protected] | (800) 956-3935 RMTG.com
SOURCE: Regenerative Medical Technology Group
View the original
press release
on ACCESS Newswire